HOSPIRA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOSPIRA, and what generic alternatives to HOSPIRA drugs are available?
HOSPIRA has five hundred and seventeen approved drugs.
There are nine US patents protecting HOSPIRA drugs. There are seven tentative approvals on HOSPIRA drugs.
There are seventy patent family members on HOSPIRA drugs in thirty-eight countries and four hundred and twenty-two supplementary protection certificates in sixteen countries.
Summary for HOSPIRA
International Patents: | 70 |
US Patents: | 9 |
Tradenames: | 333 |
Ingredients: | 210 |
NDAs: | 517 |
Patent Litigation for HOSPIRA: | See patent lawsuits for HOSPIRA |
PTAB Cases with HOSPIRA as petitioner: | See PTAB cases with HOSPIRA as petitioner |
Drugs and US Patents for HOSPIRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira Inc | LEVETIRACETAM | levetiracetam | INJECTABLE;INTRAVENOUS | 202869-001 | Apr 6, 2012 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Hospira | SODIUM BICARBONATE | sodium bicarbonate | INJECTABLE;INJECTION | 202494-001 | Mar 6, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Hospira | GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | gentamicin sulfate | INJECTABLE;INJECTION | 062414-010 | Aug 15, 1983 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Hospira | INTROPIN | dopamine hydrochloride | INJECTABLE;INJECTION | 017395-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Hospira | BUPIVACAINE HYDROCHLORIDE | bupivacaine hydrochloride | INJECTABLE;SPINAL | 071810-001 | Dec 11, 1987 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HOSPIRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hospira | BRETYLOL | bretylium tosylate | INJECTABLE;INJECTION | 017954-001 | Approved Prior to Jan 1, 1982 | RE29618 | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 4,910,214*PED | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 5,344,840 | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 6,716,867*PED | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 6,716,867*PED | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 4,910,214*PED | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOSPIRA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Injection | 100 mcg/mL | ➤ Subscribe | 2009-04-08 |
➤ Subscribe | Injection | 4 mcg/mL, 20 mL vials | ➤ Subscribe | 2015-09-30 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
➤ Subscribe | Injection | 4 mcg/mL, 50 mL and 100 mL vials | ➤ Subscribe | 2013-12-26 |
International Patents for HOSPIRA Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5990832 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2014041425 | ⤷ Sign Up |
Guatemala | 201300055 | ⤷ Sign Up |
Morocco | 37956 | ⤷ Sign Up |
Malaysia | 188598 | ⤷ Sign Up |
Hong Kong | 1207006 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for HOSPIRA Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1534313 | 2015/071 | Ireland | ⤷ Sign Up | PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728 |
2435025 | LUC00124 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
1532149 | 2011/039 | Ireland | ⤷ Sign Up | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-Y1)-7-BUT-2INYL-3-METHYL-1-(4- METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2,6-DION THE ENATIOMERS AND SALTS THEROF-ESPECIALLY LINAGLIPTIN."LINAGLIPTIN=((R)-8-(3-AMINOPIPERIDIN-1-YL)- 7-BUT-2-INYL-3-METHYL-L-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6- DION") (IUPAC); REGISTRATION NO/DATE: EU/1/11/707/001-EU/1/11/707/011 20110824 |
1746976 | 300885 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IRINOTECANSUCROSOFAATZOUT; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
0473687 | SPC/GB98/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
0253738 | C960002 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.